GenMark Diagnostics, Inc (NASDAQ: GNMK) shares are trading higher by $1.45 (18 percent) at $10.27 in Friday's session. Investors are following the lead from Cowen, which before the open upgraded the issue from Market Perform to Outperform.
This was the first rating change in the issue since July 29, when JPMorgan maintained its Overweight rating and raised its price target from $10 to $13.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Over the last 10 quarters, the company has met or beat Wall Street analyst for EPS in eight and beat analysts revenue projections on all but one of those reports. The company's next earnings report will be on October 25.
Following a sharply higher open, it retreated $0.30 to $9.74 before continuing its move higher. So far, the ensuing rally has found resistance ahead of its July 29 high ($11.31), only reaching $10.98 before retreating to the lower $10 handle.
It should be noted the issue is on track for a monster day in volume; it has already traded 1.2 million shares compared with its 20-day average of 401,000.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.